Skip to content
Research/Peptides/ARA-290 (Cibinetide)

ARA-290 (Cibinetide)

ARA-290, a non-erythropoietic peptide, represents a significant advancement in neuroprotective therapies, particularly for small fiber neuropathy. Engineered to activate the innate repair receptor (IRR) pathway, it offers tissue protection without stimulating red blood cells. Phase II clinical trials have shown efficacy in improving metabolic control and neuropathic symptoms among diabetic patients and individuals with sarcoidosis. With a promising safety profile and ongoing research into various therapeutic applications, ARA-290 is poised to make a considerable impact in neuropathy treatment.

Intelligence Profile

Science

Mechanism of Action

ARA-290 (Cibinetide) is a synthetic, non-erythropoietic peptide derived from erythropoietin that works through a distinct receptor pathway to provide tissue-protective and anti-inflammatory effects.

Receptor Binding and Signaling

ARA-290 acts as a specific ligand for the innate repair receptor (IRR), which consists of the erythropoietin receptor (EPOR) paired with the β-common receptor (CD131). This receptor complex is separate from the classical erythropoietin receptor involved in red blood cell production. Evidence shows that ARA-290 "mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke" (PMID: 38488446), confirming its interaction with this pathway.

The compound is described as targeting "the innate repair receptor axis via erythropoietin," suggesting it activates endogenous repair mechanisms through this specialized receptor system (PMID: 36211426).

Anti-Inflammatory Effects

A key mechanism involves reducing inflammatory responses across multiple tissues. Research demonstrates that ARA-290 "reduces cardiac inflammation" and shows protective effects in various inflammatory conditions (PMID: 36741836). The anti-inflammatory action appears to involve modulation of immune cell activity and cytokine production, though the precise downstream signaling cascades require further elucidation.

Tissue Protection Pathways

ARA-290 demonstrates protective effects through multiple mechanisms:

  • Apoptosis inhibition: Studies show involvement of "apoptosis and inflammation pathways" in its protective effects against drug-induced organ damage (PMID: 36085231)
  • Neural protection: The compound provides "protective effect in peripheral nerve injury" through mechanisms that appear distinct from classical erythropoietin signaling (PMID: 38943972)
  • Bone metabolism: Research indicates ARA-290 "inhibits osteoclastogenesis in vitro and increases bone mineral density in mice," suggesting effects on bone remodeling pathways (PMID: 35008482)

Clinical Translation

The mechanism translates to potential therapeutic applications in neurological conditions, metabolic disorders, and inflammatory diseases, as evidenced by clinical trials in diabetic complications, sarcoidosis-related neuropathy, and cognitive function.

Note: While the basic receptor mechanism is established, many downstream signaling details remain under investigation. The evidence base consists primarily of preclinical studies with limited clinical validation.